pocketful logo
Hikal Ltd logo

Hikal Ltd

NSE: HIKAL BSE: 524735

₹168.48

(1.53%)

Mon, 30 Mar 2026, 08:54 pm

mtf coin illustrationMTF 5x

Hikal Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    1922.26

  • Net Profit

    90.80

  • P/B

    3.91

  • Sector P/E

    31.93

  • P/E

    54.44

  • EV/EBITDA

    17.06

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    20.26

  • ROCE (Industry)

    20.84

  • RONW (Industry)

    17.81

  • ROE

    7.41

  • ROCE

    9.49

  • Debt/Equity

    0.65

  • EPS (TTM)

    2.03

  • Dividend Yield

    0.51

  • Book Value

    96.86

  • Interest Cover

    2.65

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are well covered by earnings (6.3x coverage).
  • Dividends after 3 years are expected to be thoroughly covered by earnings (9.1x coverage).
  • Hikal's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Hikal's earnings are expected to grow significantly at over 20% yearly.
thumbs up icon

Cons

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Hikal's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for Hikal is expected to increase but not above the 50% threshold in 2 years time.
  • Hikal is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
  • Hikal's revenue is expected to increase but not above the 50% threshold in 2 years time.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters68.8568.8568.8568.8568.85
FII2.304.235.365.696.06
DII7.055.164.023.803.48
Public21.7921.7621.7721.6621.61
Government0.000.000.000.000.00

Read More

Technical Analysis

RSI

28.06

MACD

-10.76

50 DMA

188.42

200 DMA

251.41

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic289.84244.39220.54198.94175.09153.49108.04
Fibonacci244.39227.03216.31198.94181.58170.86153.49
Camarilla209.18205.01200.85198.94192.51188.35184.18

Pivots Level: Classic

R3

+90.90

289.84

R2

+45.45

244.39

R1

+21.59

220.54

198.94
198.94
Pivot Point
LTP: 147.08

S1

-23.86

175.09

S2

-45.45

153.49

S3

-90.90

108.04

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    162.78

  • 20-EMA

    171.50

  • 30-EMA

    177.94

  • 50-EMA

    188.01

  • 100-EMA

    209.14

  • 200-EMA

    244.46

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
11 Feb 2026board-meetingsQuarterly Results, Interim Dividend
11 Feb 2026dividend₹0.20 Dividend /Share17 Feb 2026
17 Jan 2026dividendInterim Dividend - Re 0.20 Per Share17 Feb 2026
13 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
06 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
07 Aug 2025agm
02 Aug 2025dividendFinal Dividend - Rs. - 0.802 Sept 2025
14 May 2025dividend₹0.80 Dividend /Share02 Sept 2025
04 Feb 2025dividend₹0.60 Dividend /Share08 Feb 2025
08 Jan 2025dividendInterim Dividend - Rs. - 0.608 Feb 2025

Read More

Peer Comparison

Hikal Ltd logo

Hikal Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Lupin Ltd logo

Lupin Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Hikal Ltd About

Hikal is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1988

Headquarters

CEO

J Hiremath

Employees

Contact

Website icon

Website

http://www.hikal.com

Email icon

Email

info@hikal.com

Phone icon

Phone

91-022-3926 7100/62770477

Location icon

Location

717/718 Maker Chamber V, 7th Floor Nariman Point, Mumbai, Maharashtra, 400021

Read More

Hikal Ltd Company History

YearHistory
2017
  • Hikal won the most coveted ICC Award for Excellence in Human Resource Management in the Chemical Industry for the year 2016.
2018
  • The Global Employer Branding Institute and World HRD Congress conferred Hikal with the 'National Best Employer Brands 2018'.
  • The Company issued Bonus Shares in the Ratio of 1:2.
2019
  • Hikal was conferred with the CSR Leadership Award for Best Corporate Social Responsibility Practices by the World CSR Congress.
  • Hikal won the Confederation of Indian Industry (CII)'s 'Significant Achievement in HR Excellence' award at the CII National HR Excellence Award.
2021
  • Hikal signed a 10-year multi-product contract with a leading global pharmaceutical innovator company.
2024
  • The Company acquired a 5.73 percent stake in FPEL Ujwal Private Limited.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
QE SECURITIES LLPSell615016217.9612 Feb 2026
NK SECURITIES RESEARCH PRIVATE LIMITEDBuy2407266217.2812 Feb 2026
JUMP TRADING FINANCIAL INDIA PRIVATE LIMITEDSell900633218.1812 Feb 2026
NK SECURITIES RESEARCH PRIVATE LIMITEDSell2407266217.4112 Feb 2026
MICROCURVES TRADING PRIVATE LIMITEDSell757193218.2212 Feb 2026
MICROCURVES TRADING PRIVATE LIMITEDBuy757193218.1212 Feb 2026
QE SECURITIES LLPBuy618386217.5412 Feb 2026
JUMP TRADING FINANCIAL INDIA PRIVATE LIMITEDBuy900633217.8412 Feb 2026
HRTI PRIVATE LIMITEDBuy1732055251.0610 Dec 2025
HRTI PRIVATE LIMITEDSell1675248251.0310 Dec 2025

Read More

Hikal Ltd News

Castilia Life Sciences converts to LLP, acquires Hikal stake

Castilia Life Sciences Private Limited has converted to LLP structure, with 3,02,31,914 Hikal shares (24.52%) now vesting in the new entity following MCA approval on 17th February 2026.

18 Feb 2026

stocks

Hikal Sets Feb 17, 2026 Record Date for Interim Dividend

Hikal Limited has fixed February 17, 2026 as the record date for determining shareholder eligibility for interim dividend payment for FY 2025-26, as approved by the board on February 11, 2026.

11 Feb 2026

co actions results

Hikal Limited Q3 & 9M FY26 Earnings Call on Feb 11

Hikal Limited announces earnings conference call scheduled for February 11, 2026 at 4:30 PM IST to discuss Q3 and nine months FY26 financial and operational performance with senior management participation.

04 Feb 2026

stocks

Hikal discloses revenue recognition irregularities

Hikal Limited reports misconduct by employees involving revenue recognition irregularities affecting Q4FY25, Q1FY26, and Q2FY26, with ₹80.70 cr revenue reversal in Q2FY26. Company confirms all underlying sales are genuine.

26 Dec 2025

stocks

Hikal Ltd Shares Transfer to Castilia Life Sciences via Amalgamation Scheme

Shares of Hikal Limited previously held by Shri Rameshwara Investment Private Limited and Shri Badrinath Investment Private Limited have been transferred to Castilia Life Sciences Private Limited through an amalgamation scheme. The scheme was sanctioned under Section 233 of the Companies Act, 2013 on 18 November 2025 and became effective on 1 December 2025, affecting the shareholding structure of Hikal Limited.

05 Dec 2025

corporate action

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800